Clinical Trial Update: Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Trovax in combination with docetaxel versus docetaxel alone in progressive hormone-refractory prostate cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• TroVax

Snippet

Sponsor: The Methodist Hospital Research Institute | Conditions: Prostatic Neoplasms | Phase 2 | Status: TERMINATED